These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 19153234)

  • 1. HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide.
    Ray N; Blackburn LA; Doms RW
    J Virol; 2009 Apr; 83(7):2989-95. PubMed ID: 19153234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors.
    Ray N; Harrison JE; Blackburn LA; Martin JN; Deeks SG; Doms RW
    J Virol; 2007 Apr; 81(7):3240-50. PubMed ID: 17251281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization.
    Reeves JD; Lee FH; Miamidian JL; Jabara CB; Juntilla MM; Doms RW
    J Virol; 2005 Apr; 79(8):4991-9. PubMed ID: 15795284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.
    Labrosse B; Morand-Joubert L; Goubard A; Rochas S; Labernardière JL; Pacanowski J; Meynard JL; Hance AJ; Clavel F; Mammano F
    J Virol; 2006 Sep; 80(17):8807-19. PubMed ID: 16912327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev.
    Svicher V; Alteri C; D'Arrigo R; Laganà A; Trignetti M; Lo Caputo S; Callegaro AP; Maggiolo F; Mazzotta F; Ferro A; Dimonte S; Aquaro S; di Perri G; Bonora S; Tommasi C; Trotta MP; Narciso P; Antinori A; Perno CF; Ceccherini-Silberstein F
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2816-23. PubMed ID: 19124665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.
    Mink M; Mosier SM; Janumpalli S; Davison D; Jin L; Melby T; Sista P; Erickson J; Lambert D; Stanfield-Oakley SA; Salgo M; Cammack N; Matthews T; Greenberg ML
    J Virol; 2005 Oct; 79(19):12447-54. PubMed ID: 16160172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20).
    Lu J; Sista P; Giguel F; Greenberg M; Kuritzkes DR
    J Virol; 2004 May; 78(9):4628-37. PubMed ID: 15078945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotypic analysis of the gp41 HR1 region from HIV-1 isolates from enfuvirtide-treated and untreated patients.
    Pessoa LS; Valadão AL; Abreu CM; Calazans AR; Martins AN; Azevedo SS; Couto-Fernandez JC; Azevedo MC; Tanuri A
    J Acquir Immune Defic Syndr; 2011 Aug; 57 Suppl 3():S197-201. PubMed ID: 21857318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 gp41 genetic diversity and enfuvirtide resistance-associated mutations among enfuvirtide-naïve patients in southern China.
    Chang L; Zhao J; Guo F; Ji H; Zhang L; Jiang X; Wang L
    Virus Res; 2021 Jan; 292():198215. PubMed ID: 33166562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype.
    Cunyat F; Marfil S; García E; Svicher V; Pérez-Alvárez N; Curriu M; Perno CF; Clotet B; Blanco J; Cabrera C
    Retrovirology; 2012 Feb; 9():15. PubMed ID: 22333046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro generation of HIV type 1 subtype C isolates resistant to enfuvirtide.
    Cilliers T; Moore P; Coetzer M; Morris L
    AIDS Res Hum Retroviruses; 2005 Sep; 21(9):776-83. PubMed ID: 16218801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures.
    Tsibris AM; Hu Z; Paredes R; Leopold KE; Putcharoen O; Schure AL; Mazur N; Coakley E; Su Z; Gulick RM; Kuritzkes DR
    J Virol; 2012 Jun; 86(12):6416-26. PubMed ID: 22491471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure.
    Svicher V; Aquaro S; D'Arrigo R; Artese A; Dimonte S; Alcaro S; Santoro MM; Di Perri G; Caputo SL; Bellagamba R; Zaccarelli M; Visco-Comandini U; Antinori A; Narciso P; Ceccherini-Silberstein F; Perno CF
    J Infect Dis; 2008 May; 197(10):1408-18. PubMed ID: 18419549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo selection by enfuvirtide of HIV type-1 env quasispecies with optimal potential for phenotypic expression of HR1 mutations.
    Goubard A; Clavel F; Mammano F; Labrosse B
    Antivir Ther; 2009; 14(4):597-602. PubMed ID: 19578246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High prevalence of primary Enfuvirtide (ENF) resistance-associated mutations in HIV-1-infected patients in Hong Kong.
    Leung PH; Chen JH; Wong KH; Chan KC; Lam HY; Cheng VC; Yuen KY; Yam WC
    J Clin Virol; 2010 Mar; 47(3):273-5. PubMed ID: 20116329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity.
    Reeves JD; Miamidian JL; Biscone MJ; Lee FH; Ahmad N; Pierson TC; Doms RW
    J Virol; 2004 May; 78(10):5476-85. PubMed ID: 15113926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human immunodeficiency virus type 1 gp 41 mutations in proviral DNA among antiretroviral treatment-naive individuals from India.
    Sen S; Tripathy SP; Sahni AK; Gupta RM; Kapila K; Chopra GS; Chimanpure VM; Patil AA; Paranjape RS
    AIDS Res Hum Retroviruses; 2009 May; 25(5):521-3. PubMed ID: 19400735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of resistance to S138A substituted enfuvirtide and its application to peptide design.
    Izumi K; Kawaji K; Miyamoto F; Shimane K; Shimura K; Sakagami Y; Hattori T; Watanabe K; Oishi S; Fujii N; Matsuoka M; Kaku M; Sarafianos SG; Kodama EN
    Int J Biochem Cell Biol; 2013 Apr; 45(4):908-15. PubMed ID: 23357451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the HIV-1 env genetic context outside HR1-HR2 on resistance to the fusion inhibitor enfuvirtide and viral infectivity in clinical isolates.
    Baatz F; Nijhuis M; Lemaire M; Riedijk M; Wensing AM; Servais JY; van Ham PM; Hoepelman AI; Koopmans PP; Sprenger HG; Devaux C; Schmit JC; Perez Bercoff D
    PLoS One; 2011; 6(7):e21535. PubMed ID: 21760896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
    Reeves JD; Gallo SA; Ahmad N; Miamidian JL; Harvey PE; Sharron M; Pohlmann S; Sfakianos JN; Derdeyn CA; Blumenthal R; Hunter E; Doms RW
    Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16249-54. PubMed ID: 12444251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.